Entrada Therapeutics, Inc. (TRDA)

Key Insights

• Entrada Therapeutics reported it had approximately $296 million in cash, cash equivalents and marketable securities as of December 31, 2025, indicating a strong financial position.
• The company announced progress across its portfolio of RNA-based therapeutics, including completing dosing of Cohort 1 in a Phase 1/2 study for ENTR-601-44 and receiving regulatory authorization to initiate a Phase 1/2 study for ENTR-601-50.
• Entrada is expanding its pipeline with the selection of ENTR-801 as its first clinical candidate for ocular diseases, and plans to nominate a second ocular clinical candidate in 2026.